` RVLPQ (RVL Pharmaceuticals PLC) vs S&P 500 Comparison - Alpha Spread

RVLPQ
vs
S&P 500

Over the past 12 months, RVLPQ has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +14% growth.

Stocks Performance
RVLPQ vs S&P 500

Loading
RVLPQ
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
RVLPQ vs S&P 500

Loading
RVLPQ
S&P 500
Difference
www.alphaspread.com

Performance By Year
RVLPQ vs S&P 500

Loading
RVLPQ
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
RVL Pharmaceuticals PLC vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

RVL Pharmaceuticals PLC
Glance View

Market Cap
111 USD
Industry
Pharmaceuticals

RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. The company is headquartered in Bridgewater, New Jersey and currently employs 156 full-time employees. The company went IPO on 2018-10-12. The firm is focused on developing and commercializing eyecare and medical aesthetics products. The firm is engaged in the development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The firm delivers Upneeq (oxymetazoline hydrocholoride ophthalmic solution, 0.1%) for the treatment of acquired blepharoptosis, or low-lying eyelids, in adults. Upneeq is the non-surgical treatment option for acquired blepharoptosis.

RVLPQ Intrinsic Value
Not Available
Back to Top